Aberrant DNA Methylation in Keratoacanthoma

Area of Science:

• Dermatology
• Oncology
• Epigenetics

Background:

• Keratoacanthoma (KA) is an epidermal tumor with debated classification, sometimes resembling squamous cell carcinoma (SCC).
• Aberrant DNA methylation is common in malignant tumors but not well-studied in KA.
• Understanding KA's methylation profile is crucial for accurate diagnosis and treatment.

Purpose of the Study:

• To investigate aberrant DNA methylation in CpG islands (CGI) within keratoacanthoma (KA).
• To compare methylation patterns in KA with normal epidermis and squamous cell carcinoma (SCC).

Main Methods:

• Analysis of normal human epidermal keratinocytes (NHEKs), KA, and SCC samples using Infinium HumanMethylation450 BeadChips.
• Quantitative real-time methylation-specific PCR (RT-MSP) and bisulfite sequencing for targeted CGI analysis.
• Statistical analysis to correlate methylation levels with clinical parameters.

Main Results:

• Genome-wide analysis revealed aberrantly hypermethylated CGIs in both KA and SCC, with more in SCC.
• Specific CGIs in CCDC17, PVR, and MAP3K11 showed significantly higher methylation in KA than normal epidermis.
• PVR CGI methylation in SCC may correlate with lymph node metastasis; MAP3K11 CGI methylation in KA may correlate with age.

Conclusions:

• Aberrant DNA methylation is confirmed to occur in keratoacanthoma (KA).
• These findings contribute to classifying KA and understanding its relationship with SCC.
• Methylation patterns may serve as potential biomarkers for KA and SCC progression.